Clinical Trial: A Single-Center, Randomized, Blinded, Adjuvant- and Placebo-Controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Tolerability and Preliminarily Explore the Immunogenicity of a Split Influenza Virus Vaccine (CpG Adjuvant) in Adults Aged 18 Years and Older (China)

China, Oct. 26 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Center, Randomized, Blinded, Adjuvant- and Placebo-Controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Tolerability and Preliminarily Explore the Immunogenicity of a Split Influenza Virus Vaccine (CpG Adjuvant) in Adults Aged 18 Years and Older'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135020

Registration Time: 2026/10/23

Type: Interventional study

Primary Sponsor: Hebei Center for Disease Control and Prevention

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=347971

Published by HT Digital Content Services with permission from ...